 | |
| Clinical data | |
|---|---|
| Routes of administration | Subcutaneous |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| KEGG |
|
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C43H50N8O5S |
| Molar mass | 790.98 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Relamorelin (INN,USAN) (developmental code namesRM-131,BIM-28131,BIM-28163) is asyntheticpeptide,centrally penetrant, selectiveagonist of theghrelin/growth hormone secretagogue receptor (GHSR) which is under development byAllergan pharmaceuticals for the treatment ofdiabetic gastroparesis,chronic idiopathic constipation, andanorexia nervosa.[1][2][3] It is apentapeptide and ananalogue ofghrelin with improvedpotency andpharmacokinetics.[1][2] In humans, relamorelin produces increases inplasmagrowth hormone,prolactin, andcortisol levels,[2][4] and, like other GHSR agonists, increasesappetite.[3] As of June 2015, relamorelin is inphase IIclinical trials for diabetic gastroparesis and constipation.[5] The United StatesFood and Drug Administration (FDA) has grantedFast Track designation to relamorelin for diabetic gastroparesis.[6] The development of the drug is uncertain as the most recent mention of it was in a 2019 SEC filing from the drug manufacturer lists the drug's expected launch year as 2024, but not in subsequent filings or press releases.[7][8]
 | Thishormonal preparation article is astub. You can help Wikipedia byexpanding it. |
 | Thisdrug article relating to thegastrointestinal system is astub. You can help Wikipedia byexpanding it. |
